NPM1 Protein

Nucleophosmin 1

NPM1 Products

NPM1 Protein, Recombinant

Molecule	Species	Description	Cat. No
NPM1	Human	NPM1/Nucleophosmin Protein, Recombinant	10053-H07E

NPM1 Antibody

Molecule	Application	Description	Cat. No
Human NPM1	WB, ELISA	NPM1 / Nucleophosmin Antibody (Antigen Affinity Purified)	10053-RP02

NPM1 cDNA Clone

Molecule	Species	Description	Cat. No
NPM1	Human	Homo sapiens NPM1 cDNA Clone	HG12074-G

NPM1 Alternative Names

NPM1, B23, MGC104254, NPM [Homo sapiens]

Npm1, RP23-323L8.2, B23, MGC102162, MGC107291, NO38, Npm [Mus musculus]

NPM1 Background

Nucleophosmin 1 (NPM1), also known as nucleolar phosphoprotein B23 or numatrin, is a member of the nucleoplasmin family. Nucleophosmin (NPM) is a nucleolar phosphoprotein that plays multiple roles in ribosome assembly and transport, cytoplasmic-nuclear trafficking, centrosome duplication and regulation of p53. The NPM1 gene is frequently involved in chromosomal translocation, mutation and deletion. Mutations of the NPM1 gene leading to the expression of a cytoplasmic mutant protein, NPMc+, are the most frequent genetic abnormalities found in acute myeloid leukemias. Acute myeloid leukemias (AML) with mutated NPM1 have distinct characteristics, including a significant association with a normal karyotype, involvement of different hematopoietic lineages, a specific gene-expression profile and clinically, a better response to induction therapy and a favorable prognosis. In addition, NPM1 is a crucial gene to consider in the context of the genetics and biology of cancer. NPM1 is frequently overexpressed, mutated, rearranged and deleted in human cancer. Traditionally regarded as a tumour marker and a putative proto-oncogene, it has now also been attributed with tumour-suppressor functions.

NPM1 Related Studies

1. Chen W, et al. (2006) Nucleophosmin gene mutations in acute myeloid leukemia. Arch Pathol Lab Med. 130(11): 1687-92.
2. Naoe T, et al. (2006) Nucleophosmin: a versatile molecule associated with hematological malignancies. Cancer Sci. 97(10): 963-9.
3. Grisendi S, et al. (2006) Nucleophosmin and cancer. Nat Rev Cancer. 6(7): 493-505.
4. Falini B, et al. (2007) Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood. 109(3): 874-85.
5. Meani N, et al. (2009) Role of nucleophosmin in acute myeloid leukemia. Expert Rev Anticancer Ther. 9(9): 1283-94.